Rintatolimod Plus Durvalumab Shows Early Disease Control in Late-Stage Pancreatic Cancer
Treatment with the TLR-3 agonist rintatolimod (Ampligen) in combination with durvalumab (Imfinzi) demonstrated early disease control and safety in patients with late-stage pancreatic cancer, according to preliminary data from the phase 1b/2 DURIPANC …